Work

Targeting minimal residual disease: a path to cure?

Year: 2018

Type: review

Source: Nature reviews. Cancer

DOI: 10.1038/nrc.2017.125

Authors: Marlise R. Luskin, Mark A. Murakami, Scott R. Manalis, David M. Weinstock

Institutions: Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Koch Institute for Integrative Cancer Research At MIT, Massachusetts Institute of Technology, Broad Institute, Harvard University

Language: English

Topic: Cancer Genomics and Diagnostics

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute

Awards: Overcoming resistance in BCR-ABL-rearranged acute lymphoblastic leukemia, Quantitative and functional characterization of therapeutic resistance in cancer, Single cell growth assay for residual cells in acute lymphoblastic leukemia

OpenAlex ID: W2787046878

FWCI: 1.478

Cites: 130

Cited by: 172

Related to: 10